VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Shingrix | — | 2018-03-21 | europa.eu ↗ |
Trials 60 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04523246 | Sep 2020 → Dec 2021 | COVID-19, herpes zoster | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT03953196 | Apr → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 0 | NCT03771157 | Feb 2019 → Sep 2020 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia | University of Rochester | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07285265 | May → Nov 2025 overdue | varicella zoster infection | Suzhou Abogen Biosciences Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04210752 | Feb → Dec 2020 | herpes zoster | EyeGene Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01086449 | Mar → Jun 2010 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06569823 | Jun 2024 → Nov 2027 expected | herpes zoster | Dynavax Technologies Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05580458 | Mar 2023 → Feb 2027 expected | herpes zoster | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07614412 | Jan 2027 → Jan 2028 expected | type 1 diabetes mellitus | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07443709 | Apr → Dec 2026 expected | herpes zoster | Oriol Manuel | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07311148 | Oct 2025 → Jan 2026 overdue | herpes zoster | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05775718 | Oct 2023 → Jan 2028 expected | — | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT05554068 | Mar 2023 → Mar 2025 overdue | herpes zoster | Loyola University | Recruiting | No outcome recorded |
| Phase 2 | NCT05082688 | Sep 2021 → May 2023 | herpes zoster, influenza | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04047979 | Nov 2019 → Apr 2023 | chickenpox, herpes zoster | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT03894969 | Apr 2019 → Aug 2020 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03702231 | Dec 2018 → Sep 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT03604406 | May 2014 → Jun 2024 | herpes zoster, rheumatoid arthritis | Kevin Winthrop | Completed | No outcome recorded |
| Phase 2 | NCT01165203 | Sep 2010 → Jul 2012 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00920218 | Jul 2009 → Apr 2011 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00802464 | Jan 2009 → Jul 2010 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 324 trials | ||||||
| Phase 3 | NCT06001606 | May 2023 → Apr 2025 | herpes zoster, systemic lupus erythematosus | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04128189 | Mar 2023 → Jun 2029 expected | chronic renal failure syndrome, herpes zoster | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 3 | NCT04176939 | Dec 2019 → Aug 2022 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04091451 | Sep 2019 → Feb 2024 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03685682 | May 2018 → Sep 2019 | varicella zoster infection | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT03439657 | Apr 2018 → May 2019 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02979639 | Jan → Apr 2017 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02723773 | Apr 2016 → Jun 2023 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02735915 | Apr 2016 → Aug 2017 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02690207 | Mar 2016 → Mar 2019 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02581410 | Dec 2015 → Aug 2016 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02075515 | Aug 2014 → Apr 2015 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02058589 | Mar 2014 → May 2016 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02045836 | Mar 2014 → Jul 2015 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02052596 | Feb 2014 → Jun 2015 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01954251 | Oct 2013 → Jun 2014 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01777321 | Jun → Oct 2013 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01827839 | Jun 2013 → Feb 2014 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01751165 | Mar 2013 → May 2014 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01798056 | Mar 2013 → Jun 2015 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01767467 | Mar 2013 → Jan 2016 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01610414 | Jul 2012 → Nov 2016 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01165177 | Aug 2010 → May 2014 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01165229 | Aug 2010 → Jul 2015 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07485283 | Apr 2026 → Apr 2029 expected | cardiovascular disorder, dementia | Tor Biering-Sørensen | Recruiting | No outcome recorded |
| Phase 4 | NCT07502560 | Mar 2026 → Apr 2030 expected | herpes zoster | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 4 | NCT07280741 | Dec 2025 → Jul 2027 expected | rheumatic disorder | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06763783 | Dec 2024 → Dec 2029 expected | juvenile chronic polyarthritis, polymyalgia rheumatica, psoriatic arthritis, scleroderma +3 | Region Skane | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06162494 | Mar 2024 → Mar 2027 expected | varicella zoster infection | Ann & Robert H Lurie Children's Hospital of Chicago | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05898464 | Jun 2023 → Feb 2026 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05575830 | Dec 2022 → Apr 2025 overdue | — | Calmy Alexandra | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05596526 | Dec 2022 → Dec 2024 | herpes zoster | Prof Patrice Lalive | Unknown | No outcome recorded |
| Phase 4 | NCT05170399 | Sep 2022 → Aug 2026 overdue | lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
| Phase 4 | NCT04403139 | Apr 2022 → Dec 2026 expected | varicella zoster infection | University of Washington | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04869982 | May 2021 → Apr 2023 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03591770 | Jul 2019 → Jul 2024 | inflammatory bowel disease | Boston Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03493776 | Apr 2018 → Sep 2019 | varicella zoster infection | Deepali Kumar | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06262776 | Mar 2024 → Dec 2026 expected | immunodeficiency disease | Central Adelaide Local Health Network Incorporated | Recruiting | No outcome recorded |
| — | NCT04516408 | Apr 2021 → Sep 2023 | herpes zoster, systemic lupus erythematosus | RenJi Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 29 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06874842 Comparator | Mar 2025 → Feb 2026 overdue | herpes zoster | Guangzhou Patronus Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06409494 Comparator | Jul 2024 → Jul 2025 overdue | herpes zoster | EuBiologics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06375512 Comparator | Jul 2024 → Feb 2026 | herpes zoster | Shenzhen Shenxin Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06335849 Comparator | Mar 2024 → Sep 2025 overdue | herpes zoster | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05991427 Comparator | Nov 2023 → Nov 2024 | herpes zoster | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05718037 Comparator | Aug 2023 → Jan 2024 | herpes zoster | Wuhan BravoVax Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05871541 Comparator | May 2023 → Mar 2024 | herpes zoster | Immorna Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06137755 Comparator | Mar 2023 → Mar 2025 overdue | herpes zoster | CHA Vaccine Institute Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05769049 Comparator | Feb → Dec 2023 | herpes zoster | Jiangsu Rec-Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05636436 Comparator | Dec 2022 → Dec 2024 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05245838 Comparator | Jan → Oct 2022 | herpes zoster | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07400003 Comparator | Jan → May 2026 overdue | herpes zoster | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06932523 Comparator | Apr 2025 → Jun 2026 overdue | herpes zoster | Shanghai Institute Of Biological Products | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06801509 Comparator | Feb → Nov 2025 overdue | herpes zoster | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05703607 Comparator | Jan 2023 → Sep 2025 | herpes zoster | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT05701800 Comparator | Jan 2023 → Jun 2026 overdue | herpes zoster | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07205796 Comparator | May 2026 → Dec 2027 expected | herpes zoster | Shenzhen Shenxin Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07481604 Comparator | Apr 2026 → Jan 2027 expected | herpes zoster | CHA Vaccine Institute Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07354659 Comparator | Jan 2026 → Mar 2027 expected | herpes zoster | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06581575 Comparator | Oct 2024 → Aug 2026 overdue | herpes zoster | Immorna Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05856084 Comparator | May 2023 → Dec 2024 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05304351 Comparator | Feb 2022 → Jun 2026 overdue | herpes zoster | Curevo Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00434577 Comparator | Feb → Oct 2007 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT04748939 Comparator | Jan → Dec 2025 overdue | herpes zoster | Tuen Mun Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05550194 Background | Mar 2023 → Aug 2026 overdue | achalasia | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05007041 Comparator | Sep 2021 → Mar 2023 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT04169009 Comparator | Jul 2020 → Mar 2023 | herpes zoster | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT03798691 Comparator | May 2019 → Oct 2023 | Crohn disease, herpes zoster, ulcerative colitis | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT03886038 Comparator | Mar 2019 → Feb 2022 | rheumatoid arthritis | Region Skane | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 96 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297975 ↗ |
| Known as | 1437173A | “the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule” NCT01751165 ↗ |
| Known as | GSK1437173A | “Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered...” NCT00920218 ↗36“The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when...” NCT00920218 ↗ “The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered...” NCT01777321 ↗ “Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle...” NCT02058589 ↗ “Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.” NCT01610414 ↗ “Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2.” NCT02045836 ↗ “Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies” NCT01767467 ↗ “Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older” NCT02052596 ↗ “Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years” NCT04869982 ↗ “Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)” NCT03894969 ↗ “GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)” NCT02581410 ↗ “GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)” NCT02979639 ↗ “candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A)” NCT02979639 ↗ “Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A)” NCT02690207 ↗ “Biological: Herpes Zoster vaccine GSK 1437173A” NCT02052596 ↗ “Herpes Zoster vaccine GSK 1437173A” NCT01954251 ↗ “Herpes Zoster Vaccine GSK1437173A” NCT01954251 ↗ |
| Known as | Herpes Zoster Vaccine | “Herpes Zoster Vaccine GSK1437173A” NCT02723773 ↗ |
| Known as | Herpes Zoster vaccine (GSK1437173A) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01827839 ↗ |
| Known as | Herpes Zoster Vaccine 1437173A | “Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A” NCT00920218 ↗ |
| Known as | HZ/su | “The impact of alternate routes of vaccine administration, subcutaneous (SC) or intramuscular (IM), on the safety and immunogenicity of herpes zoster subunit candidate vaccine...” PMID 27936344 ↗ Dec 20163“assessed whether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses in previous ZVL recipients and ZVL-naive...” PMID 29029122 ↗ Dec 2017 “2 doses of a herpes zoster (HZ) subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System)” PMID 29174683 ↗ Nov 2017 “Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)” NCT04091451 ↗ |
| Known as | HZ/su vaccine | “HZ/su vaccine (GSK1437173A)” NCT04176939 ↗ |
| Known as | Recombinant Herpes Zoster Vaccine | “Recombinant Herpes Zoster Vaccine (Shingrix)” NCT07485283 ↗ |
| Known as | Recombinant varicella zoster virus (vzv) glycoprotein e | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297975 ↗ |
| Known as | Recombinant zoster vaccine | “Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years” NCT04869982 ↗11“The recombinant zoster vaccine (RZV, Shingrix®) has shown high efficacy in immunocompetent adults.” NCT07443709 ↗ “Recombinant Zoster Vaccine (CHO cell)，two-dose vaccination schedule (Month 0, 2)” NCT07354659 ↗ “Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart” NCT05898464 ↗ |
| Known as | Recombinant zoster vaccine adjuvanted | “Recombinant zoster vaccine adjuvanted (SHINGRIX)” NCT06262776 ↗ |
| Known as | RZV | “The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons...” PMID 33528118 ↗ Oct 20218“the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA)” PMID 33606577 ↗ Feb 2021 “We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients.” PMID 32103273 ↗ Oct 2021 “Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old.” NCT04516408 ↗ “The recombinant zoster vaccine (RZV, Shingrix®) has shown high efficacy in immunocompetent adults.” NCT07443709 ↗ “two doses of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®)” NCT05596526 ↗ “Intervention 1: Recombinant Zoster Vaccine (Shingrix; RZV)” NCT07614412 ↗ “Recombinant Zoster Vaccine (RZV)” NCT07280741 ↗ |
| Known as | Shingrix | “A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases...” NCT04748939 ↗54“A non-live, recombinant subunit Herpes zoster vaccine (Shingrix; GSK vaccines) was recently licensed for the prevention of shingles in people aged 50 years or older and was...” NCT03685682 ↗ “Following the initial approval of the GlaxoSmithKline (GSK) Biologicals' HZ/su vaccine, the protocol was amended to indicate that the trademark is Shingrix.” NCT03439657 ↗ “A non-live, recombinant subunit vaccine (Shingrix; GSK vaccines) was recently licensed for the prevention of shingles in people aged 50 years or older.” NCT03493776 ↗ “Participants aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).” NCT05856084 ↗ “Participants aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).” NCT07311148 ↗ “Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).” NCT06874842 ↗ “Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).” NCT05636436 ↗ “Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years” NCT04869982 ↗ “all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)” NCT06162494 ↗ “Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart” NCT05898464 ↗ “Intervention 1: Recombinant Zoster Vaccine (Shingrix; RZV)” NCT07614412 ↗ “Varicella Zoster Vaccine (Shingrix)” NCT03604406 ↗ “Treatment 5 (Shingrix)” NCT04210752 ↗ “Shingrix®” NCT07400003 ↗ |
| Known as | SRX | “The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully prevents shingles in older people.” NCT04169009 ↗ |
| Known as | Zoster Vaccine Recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05775718 ↗ |
| Known as | Zoster Vaccine Recombinant, Adjuvanted | “Zoster Vaccine Recombinant, Adjuvanted (Shingrix)” NCT05991427 ↗ |
| Modality | Vaccine | “GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).” NCT00434577 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00802464 ↗ |